Hostname: page-component-cd9895bd7-gvvz8 Total loading time: 0 Render date: 2024-12-26T17:09:22.661Z Has data issue: false hasContentIssue false

Peripheral sub-inflammation is associated with antidepressant consumption in schizophrenia. Results from the multi-center FACE-SZ dataset

Published online by Cambridge University Press:  23 March 2020

G. Fond*
Affiliation:
Schizophrenia Expert Center Fondation Fondamental, Créteil, France
O. Godin
Affiliation:
Schizophrenia Expert Center Fondation Fondamental, Créteil, France
P.M. Llorca
Affiliation:
Schizophrenia Expert Center Fondation Fondamental, Clermont-Ferrand, France
M. Leboyer
Affiliation:
Schizophrenia Expert Center Fondation Fondamental, Créteil, France
*
* Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Objectives

The relation between C-reactive protein (CRP), depression and antidepressant consumption has been well explored in major depressive disorders but not in schizophrenia, which has a high rate of depression comorbidity. The objectives of this study were:

– to determine the prevalence of abnormal CRP levels, depression and antidepressant consumption in a multi-center community-dwelling sample of subjects with schizophrenia;

– to determine the association between abnormal CRP levels, depression and antidepressant consumption in schizophrenia.

Method

Two hundred and nineteen stable patients with schizophrenia (mean age = 31.6 years, 75.3% male gender) were systematically included in the multicentre network of FondaMental Expert Center for schizophrenia (FACE-SZ) and assessed with Calgary Depression Scale for depression. High sensitivity CRP (hs-CRP) was measured with an assay using nephelometry (Dade Behring). Abnormal CRP level was defined by levels > 3 mg/L. Current medication was recorded.

Results

Overall, 63 subjects (28.8%) were found to have abnormal CRP levels, 43 (20.1%) received a diagnosis of comorbid current depression, and 51 (31.9%) had ongoing antidepressant treatment. In univariate analysis, abnormal CRP levels were found to be significantly associated with metabolic syndrome (P = 0.0011) and with antidepressant consumption (P = 0.01), while depression, psychotic symptomatology, age of onset, illness duration, sociodemographic characteristics, current tobacco or cannabis status were not (all P > 0.05).

In a multivariate model, abnormal CRP was highly associated with antidepressant consumption independently of other confounding variables (adjusted odd ratio = 2.9, 95% confidence interval 1.2–6.8).

Conclusion

Abnormal CRP levels in schizophrenia were found to be associated with antidepressant consumption, but not with depression.

Disclosure of interest

The authors have not supplied their declaration of competing interest.

Type
FC68
Copyright
Copyright © European Psychiatric Association 2016
Submit a response

Comments

No Comments have been published for this article.